Excipient Market Overview: Roquette announces restructuring post IFF Pharma buyout; WHO, FDA advance regulatory frameworks

Data Compilation
#PharmaFlow

Pipeline Prospector May 2025: Pfizer strikes US$ 6 bn oncology pact; Lilly diversifies pipeline with US$ 2.3 bn in deals

Stock Recap
#PipelineProspector

Keforal

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

30 API Suppliers, 22 USDMF, 4 JDMF, 3 EU WC, 5 NDC API, 3 Listed Suppliers, $ API Reference Price

INTERMEDIATES

4 Intermediate Suppliers

4 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

172 FDF Dossiers, 97 FDA Orange Book, 6 Europe, 6 Canada, 2 South Africa, 61 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - EQ 250MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - EQ 333MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - EQ 500MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - EQ 750MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

3 Rochem International Inc, 6 SPI Pharma, 14 DKSH, 1 Pharm-RX Chemical, 5 Faran Shimi Pharmaceutical, 5 Gangwal Healthcare, 5 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 4 ACG Worldwide, 6 Actylis, 1 Aeon Procare, 7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Ashland, 9 BASF, 1 Clariant, 7 DFE Pharma, 2 Finar, 9 Gangwal Chemicals, 1 Ideal Cures Pvt Ltd, 4 Ingredion Pharma Solutions, 26 Kerry, 1 Kima Chemical, 3 Lonza Capsugel, 13 Microlex e.U, 1 Nanjing Bold Chemical, 2 Pharmatrans-Sanaq, 5 Pluviaendo, 4 Prachin Chemical, 1 Qualicaps, 23 Roquette, 8 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 11 Sigachi Industries, 4 Silverline Chemicals, 1 The Dow Chemical Company, 1 Valens Pharmachem, 4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

62 Fillers, Diluents & Binders, 33 Thickeners and Stabilizers, 26 Disintegrants & Superdisintegrants, 23 Direct Compression, 19 Granulation, 18 Solubilizers, 17 Coating Systems & Additives, 17 Co-Processed Excipients, 15 Lubricants & Glidants, 13 Taste Masking, 13 Topical, 11 Rheology Modifiers, 10 Parenteral, 10 Film Formers & Plasticizers, 8 Empty Capsules, 7 Emulsifying Agents, 7 Controlled & Modified Release, 5 Chewable & Orodispersible Aids, 4 Surfactant & Foaming Agents, 3 API Stability Enhancers, 3 Coloring Agents

DIGITAL CONTENT

76 News #PharmaBuzz

76 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 12 Regulatory FDF Prices

MARKET PLACE

14 APIs, 4 FDF Dossiers

PATENTS & EXCLUSIVITIES

2 US Exclusivities

2 US Exclusivities

REF. STANDARDS & IMPURITIES

10 Others

10 Others

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Name of the Firm	Written Confirmation No.	Product Name	Issue Date	Valid Till	Address of the Firm
04/06/2025	Lupin Ltd	India	M/s Lupin Limited	WC-0202n	Cephalexin USP	2022-07-23	2025-07-04	198-202, New Industrial Area No.2, Mandideep-462046 Goharganj, Raisen-462046, Madhya Pradesh India
05/06/2025	Lupin Ltd	India	M/s Lupin Ltd	WC-0202A3	Cephalexin USP	2020-09-22	2022-04-07	198 - 202, New Industrial Area No. 2, Mandideep

Keforal

Keforal

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

30 API Suppliers

22 USDMF

4 JDMF

3 EU WC

5 NDC API

3 Listed Suppliers

$ API Reference Price

INTERMEDIATES

4 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

172 FDF Dossiers

97 FDA Orange Book

6 Europe

6 Canada

2 South Africa

61 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - EQ 250MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE;ORAL - EQ 333MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE;ORAL - EQ 500MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE;ORAL - EQ 750MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

3 Rochem International Inc

6 SPI Pharma

14 DKSH

1 Pharm-RX Chemical

5 Faran Shimi Pharmaceutical

5 Gangwal Healthcare

5 Nanjing Well Pharmaceutical

1 Pfanstiehl

4 ACG Worldwide

6 Actylis

1 Aeon Procare

7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

1 Ashland

9 BASF

1 Clariant

7 DFE Pharma

2 Finar

9 Gangwal Chemicals

1 Ideal Cures Pvt Ltd

4 Ingredion Pharma Solutions

26 Kerry

1 Kima Chemical

3 Lonza Capsugel

13 Microlex e.U

1 Nanjing Bold Chemical

2 Pharmatrans-Sanaq

5 Pluviaendo

4 Prachin Chemical

1 Qualicaps

23 Roquette

8 Seppic

4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

11 Sigachi Industries

4 Silverline Chemicals

1 The Dow Chemical Company

1 Valens Pharmachem

4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

62 Fillers, Diluents & Binders

33 Thickeners and Stabilizers

26 Disintegrants & Superdisintegrants

23 Direct Compression

19 Granulation

18 Solubilizers

17 Coating Systems & Additives

17 Co-Processed Excipients

15 Lubricants & Glidants

13 Taste Masking

13 Topical

11 Rheology Modifiers

10 Parenteral

CAPSULE;ORAL - EQ 250MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CAPSULE;ORAL - EQ 333MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CAPSULE;ORAL - EQ 500MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CAPSULE;ORAL - EQ 750MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons